LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
620 IndexStomatitis
patient-related risk factors for,
553, 557–558
prophylactic measures for
prevention of, 554, 558
Subcutaneous T-cell lymphoma,
419, 432
Suberoylanilide hydroxamic acid,
3, 11
Substance P, delayed CINV and,
553, 557
Substituted judgment, 585
Subtotal parathyroidectomy, 361
Sulindac, 139
Sunitinib, 289, 369, 374, 448
for GIST, 262, 266
for treatment of GIST, 374
Superior vena cava (SVC), 164,
173, 224
neoadjuvant cisplatin-based
chemotherapy for, 224
Supportive care, cancer and,
561–572
Surgical resection, for metastatic
melanoma, 377, 380
Surrogate decision makers, guiding
principles for, 581, 585
Surveillance, Epidemiology, and
End Results (SEER), 69, 74,
116, 119, 587
SVC.SeeSuperior vena cava (SVC)
SVC syndrome, causes of, 506
SV40 DNA
cancer and, 40, 53
source of, 53
SWOG.SeeSouthwest Oncology
Group (SWOG)
Syndrome of inappropriate
antidiuretic hormone
production (SIADH), 518, 522
Synovial sarcoma, 370, 373, 404
Systemic lupus erythematosus, 223
Systemic retinoids and cancer
reduction, 136, 139TAH/BSO.SeeTotal abdominal
hysterectomy/ bilateral
salpingo-oophorectomy
(TAH/BSO)
TAM.SeeTumor-associated
macrophages (TAM)
Tamoxifen, 133, 152, 158, 336,
344, 590, 594
Taxanes, 19, 27, 573, 577
Bim and, 19, 27
for metastatic thyroid carcinoma,
360
TBI-containing regimens, 526, 532
T-cell deficiency syndrome, 224T cell-lymphoma, EBV expression
in, 106, 111
T-cell–mediated immunity, 105, 110
T-cell neoplasms, 419, 432
T-cell prolymphocytic leukemia
(T-PLL), 415
T-cell receptor (TCR), 106, 111
T cells, role of, 105, 110
TCR.SeeT-cell receptor (TCR)
TD.SeeThalidomide and
dexamethasone (TD)
T3 disease and adjuvant
radiotherapy, 293
Telomerase, function of, 5, 13
Telomerase-null mice, 6
Telomeres, 13
Telophase, 17, 25
Temsirolimus, 32, 127, 288, 289
Testicular cancer
and autologous stem cell
transplantation, 530, 536
HIV and, 301
radiation therapy in, 298,
301–302
risk factors for CNS in, 297, 301
spermatic cord invasion and, 298,
301
T3 stage and, 298, 301
Testicular lymphoma, 418, 431
TGF.SeeTransforming growth
factor (TGF)
Thalidomide, 415, 465
Thalidomide and dexamethasone
(TD), 463
Thoracentesis, 173
Thoracic neurogenic tumors,
occurrence of, 215, 222
Thymic carcinoid, 218, 225
Thymic carcinoma
adjuvant chemotherapy plus
radiotherapy for, 217, 224
clear cell carcinoma and, 218, 225
Thymidylate synthase (TYMS),
123, 129, 270
Thymolipomas, 225
Thymoma, 215, 222
Thyroid carcinoma, and PET scan,
350, 358
Thyroid lymphomas, 357, 363
Thyroid malignancy, treatment of,
350, 358
Thyroid nodule, biopsy of, 357,
363
Thyroid transcription factor-1
(TTF-1), 475, 479
Time to progression (TTP), 337,
346
Tipifarnib, in AML treatment, 439,
446TIPS.SeeTransjugular intrahepatic
portosystemic shunt (TIPS)
TK.SeeTyrosine kinase (TK)
TKI.SeeTyrosine kinase inhibitors
(TKI)
T loop, phosphorylation of, 25
TLR.SeeToll-like receptors (TLR)
TME.SeeTotal mesorectal excision
(TME)
T790M mutation, 97, 101
TNF.SeeTumor necrosis factor
(TNF)
TNF, for death receptor pathway,
19, 27
TNM.SeeTumor, node, metastasis
(TNM)
Tobacco
and cancer risk, 57, 63
smoking and lung cancer, 70, 74
use and SCCHN, 195, 199
Toll-like receptors (TLR), 42, 55
Topoisomerase II inhibitor therapy,
447
Tositumomab, 430
Total abdominal hysterectomy/
bilateral
salpingo-oophorectomy
(TAH/BSO), 305
Total alopecia, chemotherapy drugs
associated with, 555, 559
Total mesorectal excision (TME),
271
Total parenteral nutrition (TPN),
571
inpatient, 566, 571
Total thyroidectomy, 349, 358
TP53 gene mutation
and Li–Fraumeni syndrome, 18,
26
in ovarian cancer, 307, 312
in pancreatic cancer, 251
T-PLL.SeeT-cell prolymphocytic
leukemia (T-PLL)
TRAIL, for death receptor pathway,
19, 27
Transabdominal sonography, 181
Transarterial chemoembolization,
contraindications for, 165,
175
Transesophageal ultrasonograpy,
216, 222–223
Transforming growth factor (TGF),
18, 54
Transjugular intrahepatic
portosystemic shunt (TIPS),
164, 174
benefits of, 164, 174
Transrectal ultrasound (TRUS),
168, 180